Beta interferon: Phase III trials will end next month.

BGEN (Cambridge, Mass.) said that its Phase III trials of beta interferon in multiple sclerosis patients will end next month, a year ahead of schedule, due to a low patient drop-out rate.

Although the trial is blinded, BGEN said it is hopeful that the low drop-out rate means that patients are experiencing low side effects. ...